BRCAPRO model underestimates BRCA1/2 mutation risk

March 21, 2014
BRCAPRO model underestimates <i>BRCA1/2</i> mutation risk

(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study published online March 17 in the Journal of Clinical Oncology.

Molly S. Daniels, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues calculated BRCAPRO scores for 589 patients with referred for at three institutions. The BRCAPRO predictions were compared with observed mutations.

The researchers found that 31 percent of patients with ovarian cancer tested positive for BRCA1 or BRCA2 mutation. More mutations were observed than expected with BRCAPRO scores <40 percent (93 mutations observed versus 34.1 mutations expected; P < 0.001). Twenty-eight percent of mutations (51 of 180) would have been missed if patients with BRCAPRO scores <10 percent had not been tested. The risk for high-grade serous ovarian cancers was underestimated with BRCAPRO, but it overestimated the risk for other histologies (P < 0.001). Underestimation increased with decreasing age at diagnosis, and there was institution-level variation in model performance (both P = 0.02).

"This study demonstrates that assessment of by a validated model cannot effectively target testing to a high-risk ovarian cancer patient population, which strongly supports the recommendation to offer BRCA1/BRCA2 genetic testing to all patients with high-grade serous ovarian cancer regardless of family history," the authors write.

Explore further: Germ-line BRCA1/2 testing recommended in ovarian cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Germ-line BRCA1/2 testing recommended in ovarian cancer

June 19, 2012
(HealthDay) -- Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, ...

Pill effects on breast, ovarian CA same in high-risk women

October 22, 2013
(HealthDay)—Among women who are BRCA1/2 mutation carriers, the associations between ever use of oral contraceptives (OCs) and ovarian and breast cancers are similar to those observed in the general population, according ...

Negative BRCA testing may not always imply lowered breast cancer risk

November 27, 2013
Women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population, according ...

Patients with BRCA1 mutations, but not BRCA2 mutations, had poorer prognosis compared with noncarriers

April 9, 2013
Patients with breast cancer who had a BRCA1 mutation had significantly worse overall and recurrence-free survival rates compared with patients without BRCA mutations, but no evidence for a difference in survival was found ...

USPSTF: BRCA testing for women with family history

April 2, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that BRCA1 and BRCA2 genetic testing be limited to women whose family histories are associated with an increased likelihood of having BRCA mutations.

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.